高级检索
当前位置: 首页 > 详情页

Forsythiaside A alleviates myocardial injury in streptozotocin-induced diabetes via endoplasmic reticulum stress-NLRP3 inflammasome pathway

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Anhui Provincial laboratory of inflammatory and immunity disease, Anhui Institute of Innovative Drugs, School of pharmacy, Anhui Medical University, Hefei 230032, PR China. [2]Department of Cardiology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan Province, PR China.
出处:
ISSN:

关键词: Forsythiaside A Diabetes Endoplasmic reticulum stress NLRP3

摘要:
The aim of this study was to evaluate for the effects of forsythiaside A (FA) on myocardial injury in streptozotocin (STZ)-induced diabetes mice. Blood glucose (BG), serum triglycerides (TG), lactate dehydrogenase (LDH), creatine kinase isoenzyme (CK-MB), cardiac troponin (cTnI), malondialdehyde (MDA), superoxide dismutase (SOD) levels were detected in STZ mice. The structure and function of heart was observed via cardiac ultrasound. Cytokine levels in mouse serum and heart were detected using enzyme-linked immunosorbent assay (ELISA) as well as TG, LDH, CK-MB, cTnI, MDA and SOD in high glucose (Glu) induced H9c2 cells. Western blot detection of the expression of endoplasmic reticulum stress-related TXNIP/NLRP3 inflammasome pathways (GRP78, PERK, P-PERK, EIF-α, P-EIF-α, XBP1, ATF6, TXNIP and NLRP3) in SCD mice and LCG induced H9c2 cells. Endoplasmic reticulum stress activator tunicamycin (TM) was used to validate the above pathway for FA. It was also found that FA had protective effects on myocardial injury in STZ mice via restored heart function, improved cardiac pathological changes and suppressed inflammatory response as well as in Glu induced H9c2 cells. In conclusion, FA alleviated myocardial injury in diabetes via endoplasmic reticulum stress-NLRP3 inflammasome pathway.Copyright © 2024 Elsevier B.V. All rights reserved.

语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2026]版:
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 药学 3 区 免疫学
JCR分区:
出版当年[2025]版:
最新[2023]版:
Q1 PHARMACOLOGY & PHARMACY Q2 IMMUNOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2025版] 出版当年五年平均 出版前一年[2024版]

第一作者:
第一作者机构: [1]Anhui Provincial laboratory of inflammatory and immunity disease, Anhui Institute of Innovative Drugs, School of pharmacy, Anhui Medical University, Hefei 230032, PR China.
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:59119 今日访问量:1 总访问量:1876 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 昆明医科大学第一附属医院 技术支持:重庆聚合科技有限公司 地址:云南省昆明市西昌路295号(650032)